相关实验视频

Updated: Sep 8, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

p53/PD-L1联合表达预测扩散大B细胞淋巴瘤的预后不佳

Yaoyao Jing^1,2,3,4, Ying Yuan⁵, Yong Yu^2,3,4,6

¹Department of Day Ward, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.

Discover oncology

|July 6, 2025

概括

在扩散型大B细胞淋巴瘤 (DLBCL) 中,p53和编程死亡配体1 (PD-L1) 的同时表达表明预后不佳. 这种p53/PD-L1共同表达并没有改善Rituximab治疗的结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种异质的血液性恶性瘤.
了解p53和编程死亡配体1 (PD-L1) 等分子标记物对于预后至关重要.
在DLBCL中p53和PD-L1共表达的预后意义需要进一步调查.

研究的目的:

评估与DLBCL患者的p53和PD-L1共同表达相关的临床特征和生存结果.
评估p53/PD-L1共同表达和临床病理特征之间的相关性.
为了确定利图西马布对DLBCL患者与p53/PD-L1共同表达的影响.

主要方法:

免疫组织化学 (IHC) 用于检测p53和PD-L1表达在176个DLBCL瘤样本中.
对临床数据和长期患者随访进行了回顾性分析.
使用统计方法来评估相关性和生存影响.

主要成果:

在DLBCL患者中,分别在44.9%,42.0%和25.6%的患者中发现了p53,PD-L1和它们的共同表达.
在非生殖中心B细胞类 (非GCB) 亚型中,p53/PD-L1的共同表达更为普遍,并且与PD-L1表达呈正相关.
具有p53/PD-L1联合表达的患者表现出明显减少的无进展生存期 (PFS) 和整体生存期 (OS).

结论:

在DLBCL中p53和PD-L1的同时表达是不良预后的独立指标.
具有p53/PD-L1共同表达的DLBCL患者似乎没有从Rituximab治疗中显著受益.
识别这种分子子组对于风险分层和潜在的治疗策略至关重要.

关键词:

扩散大的B细胞淋巴瘤.在PD-L1中.预测预后预测预测里图西马布 (Rituximab) 是一种药物.在 p53 里,p53 是一个 p53 的类型.p53/PD-L1 的共同表达.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...